Slide 1: Investor Relations Conference Call
Investor Relations Conference Call April 15, 2008 simulations plus, inc. oe
Slide 2: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 3: Introduction and Welcome
Introduction and Welcome ¢ Introduction and Welcome « Agenda — Second Fiscal Quarter FY 2008 summary — Strategy Going Forward — Questions and Answers simulations plus, inc. Us
Slide 4: Second Fiscal Quarter 2008 Summary
Second Fiscal Quarter 2008 Summary Gross revenues = $2.18 MM (decrease of 14% from 2Q07) — Pharmaceutical software and services = $1.55 MM (down 14.3% from 2Q07) + Large order received in November that was received in December last year + Pharmaceutical software and services business would have exce
Slide 5: First Six Months 2008 Summary
First Stx Months 2008 Summary Gross revenues = $4.16 MM (increase of 4.4% from 2Q07) — Pharmaceutical software and services = $2.99 MM (up 13.5% from 2Q07) + Large order received in November that was received in December last year + New business made up for more than half of the large order that was
Slide 6: Income Tax Discussion
Income Tax Discussion We hired a new tax preparer to review every quarterly report and to prepare our income tax returns We also hired a tax credit consulting firm to assist us with the complex issues related to R&D and other tax credits — This consulting firm has identified certain allowable R&D ex
Slide 7: Progress - ADMET Predictor/ADMET Modeler
Progress * ADMET Predictor/ADMET Modeler — NIH SBIR Phase I grant completed. Phase II proposal was returned unscored, which means we will not realize revenues from this source during this fiscal year — ADMET Predictor Module within both GastroPlus and ClassPharmer released (recent FDA renewal order
Slide 8: Progress - ClassPharmer and DDDPlus
Progress - 2 ClassPharmer — Continued improvements being added in response to customer requests — Molecule design capabilities showing exciting results — Tighter integration with ADMET Predictor working well — Powerful new graphics capabilities being added for next release DDDPlus — Sales increasing
Slide 9: Progress - GastroPlus
Progress - 3 GastroPlus — Version 5.3 released in October — Version 5.4 in final testing and documentation + New capability to track metabolites + New kidney model for renal clearance + New IVIVCPlus™ Module — important capability for generic and innovator companies + New PKPlus™ Module — pharmacoki
Slide 10: Progress - Words+ subsidiary
Progress - 4 * Words+ subsidiary — New Say-it! SAM PDA-based communication system is selling very well — Sales of Windows XP based systems down — new competition in the market in this product area — Continue to work on acquisition possibility, and although we are optimistic, there can be no assuranc
Slide 11: Progress - Words+ subsidiary
Progress - 4 * Words+ subsidiary — New Say-it! SAM PDA-based communication system is selling very well — Sales of Windows XP based systems down — new competition in the market in this product area — Continue to work on acquisition possibility, and although we are optimistic, there can be no assuranc
Slide 12: Employee Stock Sales and AMT
Employee Stock Sales and AMT + Employees exercise stock options at certain times for three reasons: = They are about to expire — The stock price is lower so the altemative minimum tax AMT is lower — They expect to use funds from sales of stock a year or more in the future, after the required 12-mont
Slide 13: Strategy Going Forward
Strategy Going Forward « Expand product line and services — Pharmaceutical software * Continue to seek strategic acquisition(s) — Recently discontinued negotiations with firm in Europe » Tax laws in two countries a problem » Weak dollar against Euro also a problem * Continue to enhance current produ
Slide 14: Summary
Summary Company is financially strong with excellent cash position and no debt Revenues and earnings are up for the first 6 months of this fiscal year. Growing, dedicated and extremely talented workforce Aggressive marketing and sales efforts in both businesses Acquisitions are a major part of our g
Slide 15: Questions?
Questions? simulationsplus, inc. &